Xu Zhenyu 4/A

What Happened
Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS (SOPH), was granted a total of 277,607 restricted stock units (RSUs) on April 2, 2026 — 112,936 RSUs reported as an award and 164,671 RSUs reported as a derivative award. Each unit was issued at $0.00 (typical for RSU compensation), so no cash was exchanged. The filing was amended to correct the number of ordinary shares beneficially owned following the transaction to 650,052.

Key Details

• Transaction date: April 2, 2026; reported on an amended Form 4 dated April 8, 2026 (original Form 4 filed April 3, 2026).
• Grants: 112,936 RSUs (award) + 164,671 RSUs (derivative) = 277,607 RSUs; price reported $0.00 per unit.
• Shares owned following transaction: 650,052 ordinary shares (corrected from an earlier erroneous amount).
• Vesting (per footnotes): RSU grant under the 2021 Equity Incentive Plan — 25% vests on April 2, 2027, then remaining 75% vests in equal quarterly installments through April 2, 2030 (see footnote F1).
• Amendment note (F2): This Form 4/A corrects the previously reported post-transaction beneficial ownership figure.
• Additional footnote (F3) references a separate option vesting schedule (25% on April 2, 2027, then monthly through April 2, 2030).

Context
RSUs are compensation awards that convert to ordinary shares only upon vesting; they are not an out‑of‑pocket purchase by the insider and therefore do not necessarily indicate a personal market bet. Awards are standard executive compensation and align management with long‑term shareholder interests. The important practical takeaway for investors is the amended filing correcting ownership to 650,052 shares and the vesting schedule that will release shares over 2027–2030.